Tislelizumab (BGB-A317) Plus Chemotherapy (Cisplatin/Carboplatin and Etoposide)

DRUG2 trials

Sponsors

Shanghai Pulmonary Hospital, Shanghai, China, Fudan University

Conditions

Limited Stage Lung Small Cell CarcinomaPerioperative ImmunotherapyResectable Small Cell Lung CancerSmall-cell Lung Cancer

Phase 2

Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer

Shanghai Pulmonary Hospital, Shanghai, ChinaSmall-cell Lung Cancer

Start: 2021-05-01End: 2025-11-30Target: 15Updated: 2023-05-03

Perioperative Immunotherapy for Resectable Limited-Stage SCLC

RecruitingNCT07109401

Fudan UniversityLimited Stage Lung Small Cell Carcinoma, Perioperative Immunotherapy, Resectable Small Cell Lung Cancer

Start: 2025-03-01End: 2028-12-31Target: 37Updated: 2025-08-07